Zyxin(ZYX)是一种肌动蛋白相互作用蛋白,在骨肉瘤患者中具有未知的生物学功能。这项研究旨在了解ZYX如何影响骨肉瘤细胞的生物学行为并确定相关机制。首先,ZYX在骨肉瘤中表达降低,而其较高的表达表明骨肉瘤患者预后较好.ZYX过表达显著抑制细胞增殖,迁移,和骨肉瘤细胞的侵袭,而ZYX沉默导致相反的趋势。随后,我们发现Rap1信号通路与ZYX表达显著相关,如癌症基因组图谱数据库中使用生物信息学分析报道的。此外,我们发现ZYX过表达调节Rap1/MEK/ERK轴,和骨肉瘤细胞生长,迁移,入侵也因此受到限制。此外,通过皮下给裸鼠施用肿瘤细胞,建立了移植肿瘤的小鼠模型。与对照组相比,ZYX过表达组的肿瘤更轻、更小,ZYX/Rap1轴在ZYX过表达组中被激活。一起来看,我们的结果表明ZYX抑制骨肉瘤细胞增殖,迁移,并通过调节Rap1/MEK/ERK信号通路进行侵袭。ZYX可能在骨肉瘤的临床治疗中至关重要,并且是该疾病患者的有希望的新型治疗靶标。
Zyxin (ZYX) is an actin-interacting protein with unknown biological functions in patients with osteosarcoma. This research sought to understand how ZYX affects the biological behavior of osteosarcoma cells and to identify the associated mechanism. Firstly, ZYX expression was decreased in osteosarcoma, and its higher expression indicated better outcomes in patients with osteosarcoma. ZYX overexpression significantly inhibited the proliferation, migration, and invasion of osteosarcoma cells, whereas ZYX silencing resulted in the opposite trend. Subsequently, we found that the
Rap1 signaling pathway was significantly correlated with ZYX expression as reported in The Cancer Genome Atlas\'s database using bioinformatic analysis. Moreover, we found that ZYX overexpression regulated the
Rap1/MEK/ERK axis, and osteosarcoma cell growth, migration, and invasion were consequently restrained. Additionally, by administering tumor cells subcutaneously to nude mice, a mouse model of transplanted tumors was created. Compared to the control group, the ZYX overexpression group\'s tumors were lighter and smaller, and the ZYX/
Rap1 axis was activated in the ZYX overexpression group. Taken together, our results suggest that ZYX inhibits osteosarcoma cell proliferation, migration, and invasion by regulating the
Rap1/MEK/ERK signaling pathway. ZYX might be crucial in the clinical management of osteosarcoma and is a promising novel therapeutic target in patients with this disease.